Opinion|Videos|May 19, 2025
Clinical Outcomes of Ultra-Low PSA Responses in Patients With mHSPC Receiving Darolutamide Plus ADT
Author(s)Neal Shore, MD, FACS
Research reveals that lower PSA levels in metastatic hormone-sensitive prostate cancer significantly delay disease progression and improve patient outcomes.
Advertisement
Episodes in this series
Ultra-Low PSA Responses and Clinical Outcomes
Key Themes:
- Correlation between achieving PSA <0.02 ng/mL and clinical outcomes
- Impact on time to progression and radiographic progression-free survival (rPFS)
- Overall survival trends in relation to PSA response
Expert Insights:
- Dr Shore presented data demonstrating that patients achieving ultra-low PSA levels (<0.02 ng/mL) experienced improved clinical outcomes.
The analysis showed correlations between ultra-low PSA and important end points including time to progression, rPFS, and overall survival trends
Advertisement
Related to this article
The designation was supported by findings from the phase 2 Co-PSMA trial, the phase 1/2 COBRA trial, and real-world evidence.
American Cancer Society updates prostate cancer screening guidelines, recommends regular PSA testing
The updated guidance recommends routine PSA-based screening every 2 years for average-risk men aged 50 to 69 years and annual screening beginning at age 45 for Black men or men with a strong family history of prostate cancer.
Pasritamig is being evaluated with or without JNJ-9401 in the ongoing phase 3 KLK2-comPAS trial.
These FAQs outline key recommendations from ASTRO's updated guideline on shorter-course radiation therapy for localized prostate cancer.
Updated CAPItello-281 data support capivasertib plus abiraterone in PTEN-deficient mHSPC, according to Daniel J. George, MD.
Benjamin Garmezy, MD, discusses personalizing mHSPC treatment intensification based on disease burden, molecular biomarkers, and patient-specific factors.
Biomarkers including HRR mutations, PTEN loss, and PSMA expression can guide triplet selection in mHSPC, according to Benjamin Garmezy, MD.
Alicia Morgans, MD, discusses ARACOG findings on cognitive outcomes with darolutamide vs enzalutamide and the influence of genetic dementia risk.
Advertisement
Advertisement
Trending on Urology Times
1
American Cancer Society updates prostate cancer screening guidelines, recommends regular PSA testing
2
FDA grants breakthrough therapy designation to 64Cu-SAR-bisPSMA for recurrent prostate cancer imaging
3
BCG-naïve NMIBC: Optimizing initial treatment selection
4
FDA grants De Novo authorization to Virtuoso Robotic System for bladder tumor resection
5